Phase 1 Melanoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be 18 years of age or older when you sign the consent form.
- (Phase 1a only) You must have been diagnosed with one of these advanced or spreading cancers: non-small cell lung cancer, head and neck cancer, kidney cancer, bladder cancer, or melanoma.
- (Phase 1a only) Your cancer must have continued to grow during or after standard treatments, or you were unable to tolerate those treatments, or standard treatments are not an option for you.
- You must be in generally good physical condition, able to carry out daily activities with little or no limitation (ECOG score of 0 or 1 — confirm with trial site if unsure what this means for you).
- Doctors expect you to live for at least 12 weeks or more.
- Your organs (such as kidneys, liver, and heart) must be working well enough to participate.
- You must either be unable to have children naturally, or agree to use reliable contraception during the study.
- You must be willing and able to understand what the study involves and sign a written consent form.
- (Phase 1b only) You must have confirmed advanced or spreading non-small cell lung cancer with no specific genetic mutations that have approved targeted treatments where you live, and your cancer must be measurable on scans.
Who may not be able to join:
- You have a serious heart condition or heart failure.
- You have brain or nervous system tumors that have not been treated or are currently unstable, or disease affecting the lining around the brain or spinal cord.
- You currently have another active cancer at the same time.
- You have previously received a treatment that targets a specific immune pathway called LILRB or ILT (confirm with trial site).
- You have had a life-threatening reaction to an immunotherapy treatment in the past.
- You still have significant side effects from a previous cancer treatment or surgery that have not fully resolved.
- You have an active autoimmune disease (a condition where your immune system attacks your own body).
- You have had an active infection requiring intravenous (IV) antibiotics within the 7 days before starting the study treatment.
- You are pregnant, breastfeeding, or planning to become pregnant during the study or within 6 months after your last dose of the study treatment.
- You have any other condition that, in the doctor's opinion, could interfere with your safe participation in the trial or affect the study results.
- (Phase 1b only) You have previously been treated with a drug called atezolizumab.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Phase 1a: MTD and/or RP2D of LB-LR1109 as monotherapy in participants with advanced or metastatic solid tumors / Phase 1b: MTD and/or RP2D of LB-LR1109 as combination therapy with atezolizumab in participants with advanced or metastatic NSCLC; Phase 1a: Incidence of Treatment-Emergent Adverse Events of LB-LR1109 as monotherapy / Phase 1b: Incidence of Treatment-Emergent Adverse Events of LB-LR1109 as combination therapy with atezolizumab
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.